Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The Ajinomoto Group commands a dominant share of the global amino acids market in food, feed, pharmaceutical, and other segments. Our advanced production technology and capacity to ensure stable supply of amino acid-based products is the core of our competitive strength.

https://www.ajinomoto.com/innovation/rd/acids

Revenue in healthcare and others —- 239 billion yen ~ 2 billion U.S.

https://www.statista.com/statistics/910865/ajinomoto-sales-by-segment/

Ajinomoto has amino acids/peptides but RLFTF has the 28 amino acid peptide, with the potential to dominate healthcare therapeutics and that includes domination over the vaxx sheet therapies. Are we currently burning cash while in the clutches of the NIH (why $50+ billion annual budget for these animals?) and their cronies?